The worldwide 3D printed drugs market is estimated to generate a market value of US$ 307.54 Million in 2022 and a market value of US$ 742.88 Million by 2032, with a CAGR of 9.2% from 2022 to 2032. The rising demand for personalized pharmaceuticals from various age groups might be related to the growth of the 3D-printed drugs industry.
| Data Points | Key Statistics |
|---|---|
| 3D Printed Drugs Market Value 2022 | US$ 307.54 Million |
| 3D Printed Drugs Market Projected Value (2032) | US$ 742.88 Million |
| 3D Printed Drugs Market CAGR (2022 to 2032) | 9.2% |
3D printing was invented in 1986, but it has only lately entered public attention. It has blurred the lines between science fiction and reality during the last 10 years. It is also known as Additive Manufacturing and is utilized in various industries, including automotive, aerospace and defense, retail, and medical healthcare.
The market for 3D-printed drugs is a significant component of this. 3D printing makes what was formerly pricey and inaccessible far more affordable. 3D printing is already being utilized to make replacement bones, surgical materials using 3D images to repair a broken or missing bone, and even hearing aid devices. Skull implants for those with head traumas have been developed, as have titanium heels for bone cancer sufferers.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to Future Market Insights research, global demand for 3D printed pharmaceuticals is expected to grow at a CAGR of 9.2% between 2022 and 2032, reaching a total of US$ 307.54 Million in 2032. (FMI). From 2016 through 2021, sales increased significantly at a CAGR of 6.5%.
For a long time, 3D-printed drugs have been widely employed in the healthcare industry. The use of 3D printing to make medications not only helps the healthcare sector develop quickly but also helps to save money. The COVID-19 pandemic has increased the usage of 3D-printed drugs and has had a favorable impact on the market.
As technology advances shape the pharmaceutical sector, the creation of 3D-printed drugs has advanced dramatically. Furthermore, as more individuals are diagnosed with chronic conditions, demand for 3D-printed drugs is projected to rise.
Growing Demand for Customized Medications to Accelerate the Market Growth
Several reasons contribute to the growth of 3D-printed drug sales. Their quick solubility is a significant benefit. Powder bed inkjet printing is used to create 3D-printed drugs. The drug's components are added layer by layer, similar to 3D printing for any other device.
This makes the medications simpler to swallow and can be quite beneficial for people with dysphagia. 3D printing might potentially speed up the arrival of personalized pharmaceuticals or the development of therapeutic combinations. They could be personalized for each patient, which would be far more beneficial than batch-produced medications because they would be made individually with that patient's medical history in mind.
Children may be less resistant to taking prescribed medication if 3D-printed drugs allow them to customize the form, color, style, and even flavor of the tablet! These are expected to be the primary driving forces in the 3D-printed drugs industry.
Principal Consultant
Increasing incidences of Hacking to Impede the Market Growth
Any new technology will obviously have certain drawbacks, and anticipating and mitigating them may often be a race against time. In the market for 3D printed drugs, a 3D blueprint of the patient, their medical history, the dose necessary, and so on must be created.
Patients may be hesitant to reveal their medical information for 3D printed drugs in light of recent controversies involving hacking and phishing of data kept online and on the cloud. Another problem might be mislabeled blueprints, incorrect descriptions, or having greater dose strength than claimed.
As 3D printing becomes more ubiquitous, it may be used to create illegal narcotics, which will do little to help authorities combat the growing black market trade in them. The primary problem for the commercialization of 3D-printed drugs would be a lack of regulation.
Most municipal, national, and international regulatory agencies lack specific regulations governing 3D printing. There is also debate over who will bear culpability if the drug causes an unpleasant response - the 3D printing firm, the pharmaceutical company, or the ingredients supplier.
Another issue is the global nature of medications. Drug businesses interested in the market for 3D printed drugs would need to guarantee that the appropriate packaging and user instructions are available. It can also be difficult to print pharmaceuticals in a country where there are no clear regulations governing their clearance.
Technological Advancements Are Propelling the Emergence of 3D Printed Drugs
The rising prevalence of chronic illnesses, particularly among the elderly, is driving up demand for 3D-printed drugs in North America. Furthermore, the availability of great domestic healthcare infrastructure in the USA and Canada is driving the expansion of 3D-printed drugs.
Strong investment in research and development, as well as increased usage of technology breakthroughs, is driving up demand for 3D-printed drugs in North America. As a result of the aforementioned factors, North America is predicted to have 31.1% of the market for 3D-printed drugs in 2022.
The Expansion of the Pharmaceutical Business is Boosting the Rise of 3D Printed Drugs
The prominent position of pharmaceutical corporations in the United Kingdom, as well as their strong domestic healthcare infrastructure, is helping the expansion of the 3D-printed drugs industry.
Furthermore, the pharmaceutical industry is heavily reliant on research and development investment, which explains why the market is expanding. As a result of the aforementioned factors, Europe is predicted to have a 29.9% market share by 2022.
Emerging Economies are Generating Attractive Potential for 3D Printed Drugs Research
Significant technical integration of 3D printed drugs techniques by China and Japan is driving the growth of the Asia Pacific 3D printed drugs industry. Furthermore, the usage of technology is altering the region's 3D-printed drugs industry.
The expansion of emerging nations such as India and Australia's healthcare infrastructure, Research and Development, and clinical development frameworks has positioned the Asia Pacific market to see attractive prospects and growth throughout the projection period. As a result, Asia Pacific is estimated to represent 27% of the market in 2022.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Simple installation and reduced waste speed up the manufacture of 3D-printed drugs in hospitals and clinics.
The increasing demand for medicines and the cost-effective usage of bio-drugs using this technology is driving the growth of hospitals and clinics. Furthermore, the expanding usage of prescription medications to treat a wide range of chronic disorders is increasing reliance on tailored medicines.
It may also significantly reduce costs, waste, and environmental strain. Furthermore, these printers may be put in hospitals and clinics to enable the on-demand production of pharmaceuticals, particularly those with low stability or that require cold chain storage. As a result, hospitals and clinics are estimated to hold 45% of the market for 3D-printed drugs.
Technological advancements make inkjet printers easier to use
Inkjet printing involves spraying various combinations of active pharmacological ingredients and excipients (inks) through a nozzle to deposit three-dimensional structures in solid dosage forms. Inkjet technology produces 3D drugs at a consistent rate and provides technological advantages over other procedures. Furthermore, it has a high patient adoption rate.
Furthermore, rising epilepsy rates, technical breakthroughs in 3D printing technology, and growing awareness of this technology in emerging markets are key market development factors. As a result, inkjet printer technology is estimated to account for 24% of the market for 3D-printed drugs in 2022.
Hewlett Packard Caribe, Merck, Cycle Pharmaceuticals, AstraZeneca, Aprecia, Osmotica Pharmaceuticals, Aprecia Pharmaceuticals LLC Extend Biosciences, Bioduro, Affinity Therapeutics, GlaxoSmithKline Plc, and FabRx Ltd are key participants in the 3D printed drugs industry.
Recent Developments
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 9.2% from 2022 to 2032 |
| Market Value in 2022 | US$ 307.54 Million |
| Market Value in 2032 | US$ 742.88 Million |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in US$ Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Dosage Form, Technology, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; The Middle East and Africa (MEA) |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, Russia, Poland, China, Japan, South Korea, India, ASIAN, Oceania, GCC Countries, South Africa, Turkey |
| Key Companies Profiled | Hewlett Packard Caribe; Merck; Cycle Pharmaceuticals; AstraZeneca; Aprecia; Osmotica Pharmaceuticals; Aprecia Pharmaceuticals LLC; Extend Biosciences; Bioduro; Affinity Therapeutics; GlaxoSmithKline Plc; FabRx Ltd |
By 2022 end, sales of 3D Printed Drugs closed at a value of US$ 307.54 Million
From 2017 to 2021, 3D Printed Drugs demand expanded at a CAGR of 6.5%
From 2022 to 2032, 3D Printed Drugs sales are expected to flourish at a CAGR of 9.2%
By 2032, the market value of 3D-printed drugs is expected to reach US$ 742.88 Million
By technology, inkjet 3D printed drugs are expected to dominate the market in 2022.
1. Executive Summary | 3D Printed Drugs Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2016 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2016 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Dosage Form
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Dosage Form, 2016 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dosage Form, 2022 to 2032
5.3.1. Tablets
5.3.2. Capsules
5.3.3. Multi-Drug Implants
5.3.4. Nanoparticles
5.3.5. Solutions
5.3.6. Others
5.4. Y-o-Y Growth Trend Analysis By Dosage Form, 2016 to 2021
5.5. Absolute $ Opportunity Analysis By Dosage Form, 2022 to 2032
6. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Technology
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2016 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2022 to 2032
6.3.1. Inkjet Printing
6.3.2. Direct Write
6.3.3. Zip Dose
6.3.4. Thermal Inkjet Printing
6.3.5. Fused Deposition Modelling
6.3.6. Powder Bed Printing
6.3.7. Stereo Lithography (SLA)
6.3.8. Semi-Solid Extrusion (SSE)
6.4. Y-o-Y Growth Trend Analysis By Technology, 2016 to 2021
6.5. Absolute $ Opportunity Analysis By Technology, 2022 to 2032
7. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2016 to 2021
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2016 to 2021
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Dosage Form
8.2.3. By Technology
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Dosage Form
8.3.3. By Technology
8.4. Key Takeaways
9. Latin America Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2016 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Dosage Form
9.2.3. By Technology
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Dosage Form
9.3.3. By Technology
9.4. Key Takeaways
10. Europe Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2016 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Dosage Form
10.2.3. By Technology
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Dosage Form
10.3.3. By Technology
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2016 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Rest of Asia Pacific
11.2.2. By Dosage Form
11.2.3. By Technology
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Dosage Form
11.3.3. By Technology
11.4. Key Takeaways
12. Middle East and Africa Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2016 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of Middle East and Africa
12.2.2. By Dosage Form
12.2.3. By Technology
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Dosage Form
12.3.3. By Technology
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Dosage Form
13.1.2.2. By Technology
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Dosage Form
13.2.2.2. By Technology
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Dosage Form
13.3.2.2. By Technology
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Dosage Form
13.4.2.2. By Technology
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Dosage Form
13.5.2.2. By Technology
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Dosage Form
13.6.2.2. By Technology
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Dosage Form
13.7.2.2. By Technology
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Dosage Form
13.8.2.2. By Technology
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Dosage Form
13.9.2.2. By Technology
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Dosage Form
13.10.2.2. By Technology
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Dosage Form
13.11.2.2. By Technology
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Dosage Form
13.12.2.2. By Technology
13.13. GCC Countries
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Dosage Form
13.13.2.2. By Technology
13.14. South Africa
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Dosage Form
13.14.2.2. By Technology
13.15. Israel
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Dosage Form
13.15.2.2. By Technology
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Dosage Form
14.3.3. By Technology
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Aprecia
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. FabRx LTD
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Extend Biosciences
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Bioduro
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Affinity Therapeutics
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Tvasta
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Merck KGaA
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Terumo Corporation
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Cycle Pharmaceuticals
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. AstraZeneca
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
15.1.11. GlaxoSmithKline Plc
15.1.11.1. Overview
15.1.11.2. Product Portfolio
15.1.11.3. Profitability by Market Segments
15.1.11.4. Sales Footprint
15.1.11.5. Strategy Overview
15.1.11.5.1. Marketing Strategy
15.1.12. Osmotica Pharmaceuticals
15.1.12.1. Overview
15.1.12.2. Product Portfolio
15.1.12.3. Profitability by Market Segments
15.1.12.4. Sales Footprint
15.1.12.5. Strategy Overview
15.1.12.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
3D Printed Drugs Market
